GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shattuck Labs Inc (NAS:STTK) » Definitions » Effective Interest Rate on Debt %

STTK (Shattuck Labs) Effective Interest Rate on Debt % : 0.00% (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shattuck Labs Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Shattuck Labs's annualized positive value of Interest Expense for the quarter that ended in Dec. 2024 was $0.00 Mil. Shattuck Labs's average total debt for the quarter that ended in Dec. 2024 was $3.51 Mil. Therefore, Shattuck Labs's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 was 0.00%.


Shattuck Labs Effective Interest Rate on Debt % Historical Data

The historical data trend for Shattuck Labs's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shattuck Labs Effective Interest Rate on Debt % Chart

Shattuck Labs Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Effective Interest Rate on Debt %
Get a 7-Day Free Trial - - - - -

Shattuck Labs Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Shattuck Labs's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Shattuck Labs's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shattuck Labs's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shattuck Labs's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Shattuck Labs's Effective Interest Rate on Debt % falls into.


;
;

Shattuck Labs Effective Interest Rate on Debt % Calculation

Shattuck Labs's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2023 )+Total Debt  (A: Dec. 2024 ))/ count )
=-1  *  0/( (4.202+3.406)/ 2 )
=-1  *  0/3.804
=0.00 %

where

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.406 + 0.796
=4.202

Total Debt  (A: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.506 + 0.9
=3.406

Shattuck Labs's annualized Effective Interest Rate on Debt % for the quarter that ended in Dec. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Sep. 2024 )+Total Debt  (Q: Dec. 2024 ))/ count )
=-1  *  0/( (3.615+3.406)/ 2 )
=-1  *  0/3.5105
=0.00 %

where

Total Debt  (Q: Sep. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.742 + 0.873
=3.615

Total Debt  (Q: Dec. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.506 + 0.9
=3.406

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Dec. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Shattuck Labs  (NAS:STTK) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Shattuck Labs Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Shattuck Labs's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Shattuck Labs Business Description

Industry
Traded in Other Exchanges
N/A
Address
500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
Executives
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Taylor Schreiber director, officer: Chief Executive Officer 100 EUROPA DRIVE, CHAPEL HILL NC 27517
Tyler Brous director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Stephen Stout officer: See Remarks C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Andrew R Neill officer: See Remarks 1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703
George Golumbeski director C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Abhinav A. Shukla officer: Chief Technical Officer 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Carrie Brownstein director 500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Erin Ator Thomson officer: General Counsel 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Josiah Hornblower director, 10 percent owner, officer: Chairman 3317 BOWMAN AVE, AUSTIN TX 78703
Neil W Gibson director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Helen M Boudreau director 200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Arundathy N. Pandite officer: Chief Medical Officer 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Victor Stone director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Casi Deyoung officer: Chief Business Officer C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744